Longitude Capital is a California-based investment firm focused on venture growth in life sciences, including biotechnology and medical technology companies. Founded in 2006, it targets both privately held and publicly traded life science companies and pursues a balanced portfolio of clinical-stage and commercial-stage assets with the potential for value creation within three to five years. The firm identifies opportunities through its broad industry network and thematic research into emerging therapeutic areas or sub-sectors, and uses a range of investment structures including traditional venture capital, asset spin-outs, recapitalizations, PIPEs, open market purchases, royalties, and other equity-linked instruments. It maintains offices in Menlo Park, Greenwich, and Boston and operates as a registered investment adviser.
Amarin is a biopharmaceutical company focused on cardiovascular health, developing and commercializing therapeutics to reduce cardiovascular risk. Its lead product is Vascepa, a prescription omega-3 fatty acid capsule indicated to lower triglyceride levels in adults when used with diet, with development efforts including the REDUCE-IT program for patients with high triglycerides on statin therapy. The firm concentrates on lipid science and the therapeutic benefits of polyunsaturated fatty acids. It markets products primarily through wholesalers and specialty pharmacies via direct sales and maintains collaborations, including a development partnership with Mochida Pharmaceutical Co. Ltd. for products based on the active omega-3 ingredient in Vascepa. The company is headquartered in Dublin, Ireland, with research and development activities in Mystic, Connecticut, and was established in 1989 after formerly being named Ethical Holdings plc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.